BLUETTI
21.2.2024 06:25:27 CET | Business Wire | Press release
BLUETTI, a leading innovator in green energy storage solutions, announces the official launch of its ground-breaking SwapSolar ecosystem on Indiegogo on February 21 at CET 3 pm. Debuted at CES 2024, SwapSolar introduces the world's first LFP-powered MultiCooler portable fridge and the AC180T hot-swappable battery power station, redefining convenience and functionality for outdoor enthusiasts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220126870/en/
BLUETTI SwapSolar (Photo: Business Wire)
James Ray, BLUETTI's spokesperson, captures the essence of SwapSolar: "We want users to savor the joy of outdoor life. SwapSolar is your ticket to 3-6 days of happy camping trip. Power up and keep your food fresh, it's time to go wild with BLUETTI!”
BLUETTI MultiCooler: 3-in-1 Portable Fridge
The MultiCooler is a versatile appliance that combines ice-making, refrigeration, and freezing in one sleek design. With a temperature range of -20℃ to +20℃ and a capacity of 40L , it covers various refrigeration needs. The powerful compressor provides rapid cooling from 30℃ to 0℃ in just 15 minutes, complemented by a built-in ice maker for crystal-clear cubes in minutes.
The MultiCooler weighs approximately 25kg with wheels and a drawbar for effortless transport. It operates quietly at 30 dB and supports Bluetooth connectivity for remote control. With four charging methods, including wall outlets, vehicles, solar panels, and the AC180T’s battery(lasting for 3 days per pack), the MultiCooler ensures constant cooling on the go.
BLUETTI AC180T: Hot-Swappable Battery Power Station
The AC180T introduces a removable battery design that allows users to easily replace its two 716,8Wh LFP batteries. It can operate with either one or two batteries, while its power and charging vary accordingly.
Users can customize their power needs anytime by purchasing additional battery packs. The AC180T can provide 1.800W of power for most devices and supports fast 1.440W AC charging and solar charging for quick refreshment.
Pricing and Availability
BLUETTI offers a 5-year warranty for the AC180T and a 2-year warranty for the MultiCooler. Join the Indiegogo campaign starting February 21 at CET 3 pm to enjoy the best Super Early Bird offers on limited quantities.
About BLUETTI
Committed to a sustainable future, BLUETTI provides affordable green energy storage solutions for both indoor and outdoor use. With a diverse product portfolio tailored for adventures, emergency backup power, and off-grid living, BLUETTI is an industry leader present in 100+ countries, trusted by millions of customers worldwide.
Source: BLUETTI EU Marketing
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220126870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom